[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Veru Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy

04/11/2022

Less than a minute

2022.04.11 14:26

Veru Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy
Veru (VERU) Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy

Veru Inc. (NASDAQ:VERU) shares are gaining over 30% in heavy pre-market trading after the company announced that its COVID-19 drug candidate reduced deaths by 55% in hospitalized COVID patients in Phase 3 trial. Due to the “overwhelming” efficacy of the study, Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 study be halted, and they further remarked that no safety concerns were identified.

Source

04/11/2022

Less than a minute